Importance of familial predisposition to heart failure to the risk of anthracycline-related cardiotoxicity: A nationwide study - 11/10/23
, Charlotte Andersson, MD, PhD b, Maria D'Souza, MD, PhD c, Emil Fosbøl, MD, PhD d, Dorte Nielsen, MD, DMsc e, f, Christian Torp Pedersen, MD, DMsc g, Gunnar H. Gislason, MD, PhD c, f, h, i, Jacob Eifer Møller, MD, DMsc a, d, j, Lars Køber, MD, DMscd e, f, Christian Madelaire Rasmussen, MD, PhD a, Morten Schou, MD, PhD kRésumé |
Background |
Anthracycline-based chemotherapy has improved the prognosis of various malignancies, but increases the long-term risk of heart failure (HF). Identification of patients at risk prior to treatment initiation is warranted. Therefore, the aim of this study was to evaluate if a familial predisposition to HF increases the risk of anthracycline related HF.
Methods |
Using nationwide Danish registries, all patients treated with anthracycline from 2004 to 16 were identified. The primary outcome was long-term HF risk. First-degree relatives were identified in the Danish Family Registry and exposure was defined as a first-degree biological relative with prior HF. Risk of HF was evaluated in a cumulative incidence function and the association in a multivariable Cox regression model.
Results |
A total of 11,651 patients (median age 49.1 years (IQR: 43.6-53.7), 12.2% male) were included after exclusion of 46 with preanthracycline HF. Median follow-up was 3.8 years (IQR 1.9-6.4). In the group with a first-degree relative with HF (n = 1,608) 35 patients (2.2%) were diagnosed with HF vs 133 (1.3%) in the group without a first-degree relative with HF (n = 10,043), corresponding to incidence rates per 1,000 patient-years of 5.2 (CI:3.8-7.3) vs 3.0 (CI:2.5-3.5). The cumulative incidence of HF after 10 years was higher in the first-degree relative group (3.2% vs 2.0%, P = .004); adjusted hazard ratio 1.53 (CI:1.05-2.23, P = .03).
Conclusion |
In this nationwide register-based study having a first-degree relative with HF was associated with increased risk of anthracycline related HF, suggesting that attention towards family predisposition may be warranted when estimating the risk of anthracycline related cardiotoxicity.
Le texte complet de cet article est disponible en PDF.Plan
Vol 265
P. 59-65 - novembre 2023 Retour au numéro
Article précédent
- Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF
- Anthony E. Peters, Nicole Solomon, Karen Chiswell, Gregg C. Fonarow, Michel G. Khouri, Lori Baylor, Jose Alvir, Marianna Bruno, Ahsan Huda, Larry A. Allen, Kavita Sharma, Adam D. DeVore, Stephen J. Greene
- Cardiovascular hospitalizations for Medicare advantage beneficiaries in the United States, 2009 to 2019
- Andrew S. Oseran, Huaying Dong, Rishi K. Wadhera
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?